Boston, USA-based clinical-stage biopharma Odyssey Therapeutics announced the closing of a $213 million Series D financing.

Precision for Medicine, a next-generation provider of drug research and development services, today announced that Dr ...

The Inflation Reduction Act has rewritten the rules of US drug economics. Negotiated prices and a Part D redesign have ...

US pharma giant Merck & Co today announced positive results from the Phase III STRIDE-13 trial evaluating Capvaxive ...

UK government-backed agency the Medicines Discovery Catapult (MDC) and Crown Bioscience have formed a strategic global ...

Privately-held US drug developer Capsida Biotherapeutics has shared the news that the first patient to participate in its SYNRGY trial for STXBP1-Related Disorders passed away.

Following on from the San Francisco-based firm’s attempts to sell compounded GLP-1 agonists to the weight loss market—whether ...

The Trump administration has announced its intent to levy tariffs on pharmaceutical products and proposed lowering drug ...

A new analysis from Phesi of 583 recruiting clinical trials or trials about to start involving GLP-1 receptor antagonists ...

Danish CNS specialist Lundbeck is flexing its muscles in the competitive migraine space with a comprehensive collection of ...

Despite recent declines, opioids remain commonly prescribed to about one in five \us adults who live with chronic pain as ...

US drugmaker Merck & Co, known as MSD outside of North America, has scrapped a £1 billion ($1.35 billion) research center in ...